Latest news
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Maxion Therapeutics Expands Team and Facilities with Move to Unity Campus
Maxion Therapeutics Wins ‘Start-up of the Year’ at 2023 Cambridge Independent Science & Technology Awards
Maxion Therapeutics Awarded £2 million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-to-Treat" Autoimmune Diseases
Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Maxion Therapeutics strengthens its Board with the appointment of Ian Tomlinson (Chairman), Tom Weaver (Non-Executive Director), and Aneesh Karatt Vellatt (Director)
News
